PACBHealthcare · Medical DevicesThe 8 Wall Street analysts covering Pacific Biosciences of California, Inc. hold a median 12-month price target of $2 — +53.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 44 of 100 as at 12 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Pacific Biosciences of California, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (96): Sales and profits are climbing, and climbing faster than before.
Issuance (30): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PACB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +53.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Sept 2026 | UBS | Assumes | Neutral | $1.50 → $1.35 |
| 11 May 2026 | Barclays | Maintains | Underweight | $1.00 → $1.50 |
| 11 May 2026 | Barclays | Maintains | Underweight | — |
| 14 Apr 2026 | Barclays | Maintains | Underweight | — |
| 6 Mar 2026 | Barclays | Downgrade | Underweight | — |
| 15 Dec 2025 | Barclays | Maintains | Equal-Weight | — |
| 11 Nov 2025 | Piper Sandler | Maintains | Neutral | — |
| 10 Nov 2025 | Stephens & Co. | Maintains | Overweight | — |
| 11 Aug 2025 | Piper Sandler | Maintains | Neutral | — |
| 25 June 2025 | Barclays | Maintains | Equal-Weight | — |
| 15 May 2025 | Piper Sandler | Maintains | Neutral | — |
| 15 May 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 10 Apr 2025 | Canaccord Genuity | Maintains | Buy | — |
| 25 Mar 2025 | Scotiabank | Maintains | Sector Outperform | — |
| 20 Feb 2025 | Piper Sandler | Reiterates | Neutral | — |
| 18 Feb 2025 | Goldman Sachs | Maintains | Neutral | — |
| 18 Feb 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 14 Feb 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 23 Jan 2025 | Goldman Sachs | Maintains | Neutral | — |
| 11 Nov 2024 | Piper Sandler | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PACB appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Pacific Biosciences of California, Inc. returned +3.2% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 81% of US stocks
Cheaper than 46% of US stocks
Cheaper than 98% of US stocks
Cheaper than 54% of US stocks
Higher than 24% of US stocks
Higher than 34% of US stocks
Higher than 37% of US stocks
Higher than 13% of US stocks
Higher than 7% of US stocks
Higher than 2% of US stocks
Higher than 23% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Pacific Biosciences of California, Inc. has a market value of $404.1M and an enterprise value of $876.3M.
Revenue in the twelve months to 30 June 2026: $159.3M. The latest quarter shrank 1.9% year on year.
Net income over the same four quarters: −$131.4M, a −82.5% net margin.
Diluted earnings per share, trailing twelve months: $−0.43.
Free cash flow in the twelve months to 30 June 2026: −$130.5M.
Trailing P/E: −0.7×; forward P/E: −3.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Pacific Biosciences of California, Inc. employs 485 people — $328K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Pacific Biosciences of California, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Pacific Biosciences of California (PACB) closed at $1.27 in the latest trading session, down 1.55% from the previous day. The stock declined more than the broader market.
Why it matters — The stock underperformed the broader market in the latest session, which is a notable negative signal for investors tracking PACB's daily price action.
Pacific Biosciences reported earnings 30 days ago, and its stock has risen 11.6% since that report. Zacks Investment Research examines whether the stock can continue this momentum.
Why it matters — This item tracks PACB's post-earnings share price movement and assesses whether recent gains can be sustained, information relevant to investors following the company.
PacBio announced that its management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference, scheduled for Tuesday, September 15, 2026, at 4:50 PM ET in New York, New York.
Why it matters — The announcement gives PACB watchers a scheduled opportunity to hear directly from company management in a prominent investor-facing healthcare forum.
PacBio cut its 2026 revenue outlook, citing weaker instrument demand and a slower SPRQ-Nx transition. The company said the lowered guidance raises the stakes for clinical adoption of its technology.
Why it matters — A PACB watcher would care because the revised outlook signals softer near-term instrument demand and uncertainty around how quickly the SPRQ-Nx transition can drive adoption.
On August 19, 2026, Merck and Moderna announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy combined with Keytruda in resected melanoma. The results were reported to have lifted five biotech names.
Why it matters — A PACB watcher would care because positive cancer-treatment developments and strength across biotech names can indicate broader sector momentum that may affect genomics companies like Pacific Biosciences.
The 8 Wall Street analysts covering Pacific Biosciences of California, Inc. have a median 12-month price target of $2, with estimates ranging from $1.25 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Pacific Biosciences of California, Inc., 4 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Pacific Biosciences of California, Inc. 44 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Pacific Biosciences of California, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (96 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +53.8% from the last close, and Ticker Nerd's factor model ranks Pacific Biosciences of California, Inc. 44 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Pacific Biosciences of California, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PACB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.25 to $3 over the next 12 months.
Pacific Biosciences of California, Inc. returned +3.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Pacific Biosciences of California, Inc. Common Stock represents Pacific Biosciences of California, Inc., a life science technology company focused on designing, developing, and manufacturing advanced DNA sequencing solutions.
The most recent item we track (Zacks Investment Research, 10 Sept 2026): "Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know". Pacific Biosciences of California (PACB) closed at $1.27 in the latest trading session, down 1.55% from the previous day. The stock declined more than the broader market.
Pacific Biosciences of California, Inc. Common Stock represents Pacific Biosciences of California, Inc., a life science technology company focused on designing, developing, and manufacturing advanced DNA sequencing solutions. The company’s products support genetic and genomic analysis for researchers and clinical scientists working on complex biological questions. Its portfolio centers on integrated sequencing platforms and related consumables and software used in laboratories that study genome structure, variation, and regulation. PacBio serves customers across academic research, biotechnology, pharmaceutical, and clinical markets, where high-accuracy sequencing tools are used to generate detailed genetic data. The company operates from Menlo Park, California, and is recognized for its role in the broader molecular diagnostics and genomics tools industry.
CEO Mr. Mark Van Oene Ph.D. · 485 employees · United States · https://www.pacb.com
